Silencing of Eag1 Gene Inhibits Osteosarcoma Proliferation and Migration by Targeting STAT3-VEGF Pathway

Area of Science:

• Oncology
• Molecular Biology
• Channelopathies

Background:

• The role of Ether à go-go 1 (Eag1) potassium channels in cancer progression, particularly osteosarcoma, is not well understood.
• Eag1 channels are implicated in various cellular functions, but their specific contribution to osteosarcoma migration and invasion requires elucidation.

Purpose of the Study:

• To investigate the impact of Eag1 knockdown on osteosarcoma cell proliferation, apoptosis, migration, and invasion.
• To explore the relationship between Eag1, signal transducer and activator of transcription 3 (STAT3), and vascular endothelial growth factor (VEGF) in osteosarcoma.

Main Methods:

• Osteosarcoma cells were treated with Eag1 small interfering RNAs (siRNAs) to assess proliferation, apoptosis, migration, and invasion.
• Expression levels of VEGF and STAT3 were measured following Eag1 knockdown.
• STAT3 siRNA was used to confirm the role of the STAT3-VEGF pathway.

Main Results:

• Eag1 knockdown significantly suppressed osteosarcoma cell proliferation and tumor growth in vivo, with minimal impact on apoptosis.
• Osteosarcoma cell adhesion, migration, and invasion were markedly reduced upon Eag1 silencing.
• VEGF and STAT3 expression levels decreased following Eag1 siRNA treatment, and STAT3 downregulation mimicked the effects of Eag1 silencing on proliferation and migration.

Conclusions:

• Eag1 promotes osteosarcoma proliferation and migration.
• The Eag1-mediated promotion of osteosarcoma progression occurs, at least partly, through the STAT3-VEGF signaling pathway.
• Targeting Eag1 may represent a viable therapeutic strategy for osteosarcoma treatment.